• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Celcuity Inc. (Amendment)

    2/14/24 4:34:04 PM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email
    SC 13G/A 1 d700479dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Celcuity Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    15102K100

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 15102K100

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,481,300

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,481,300

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,481,300

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 15102K100

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,481,300

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,481,300

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,481,300

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 15102K100

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,481,300

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,481,300

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,481,300

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).

    Name of Issuer:

    Celcuity Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    16305 36th Avenue North, Suite 100

    Minneapolis, MN 55446

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.001 par value per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    15102K100

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 24,203,156 outstanding shares of Common Stock as reported by the Issuer in its prospectus supplement filed on November 29, 2023.


    The Master Fund directly holds 1,481,300 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own shares held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares held by the Master Fund.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    /s/ Joseph Edelman
    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    Get the next $CELC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    7/22/2024$29.00Outperform
    Leerink Partners
    2/22/2024$40.00Buy
    Stifel
    12/8/2023$27.00Buy
    H.C. Wainwright
    10/8/2021$50.00Buy
    Canaccord Genuity
    9/7/2021$48.00Buy
    Jefferies
    7/29/2021Outperform
    Cowen
    7/27/2021$50.00Buy
    Needham
    More analyst ratings

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

      MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit at 9:30 a.m. ET on Wednesday, May 28, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/cowen180/celc/1978947; andA fireside chat at the Jefferies Global Healthcare Conference at 7:35 a.m. ET on Thursday, June 5, 2025. A live webc

      5/21/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancerApproximately $206 million in cash, cash e

      5/14/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

      MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information  To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this

      5/7/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    SEC Filings

    See more
    • SEC Form 8-K filed by Celcuity Inc.

      8-K - Celcuity Inc. (0001603454) (Filer)

      5/16/25 5:00:15 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Celcuity Inc.

      10-Q - Celcuity Inc. (0001603454) (Filer)

      5/15/25 5:00:26 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Celcuity Inc. (0001603454) (Filer)

      5/14/25 4:34:44 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

      SC 13G/A - Celcuity Inc. (0001603454) (Subject)

      11/14/24 5:46:12 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

      SC 13G/A - Celcuity Inc. (0001603454) (Subject)

      11/14/24 5:46:16 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Celcuity Inc.

      SC 13G - Celcuity Inc. (0001603454) (Subject)

      11/14/24 4:26:12 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Leadership Updates

    Live Leadership Updates

    See more

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Celcuity Appoints Eldon Mayer as Chief Commercial Officer

      MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

      2/20/24 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

      Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors."We are delighted to welcome Dr. Murphy to our Board and look forward to leveraging her business development expertise and broad industry experience as we continue to advance our pipeline," said Brian Sullivan, CEO and Co-Founder of Celcuity.Dr. Murphy joins Cel

      9/14/22 9:00:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

      MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. Michael Snitkovsky joined Celcuity as VP of Program Management and David Bridge joined as VP of Quality Assurance and Process Development."We are pleased to welcome Michael and David to the Celcuity leadership team. Each brings extensive experience across the biopharmaceutical development spectrum, and each has a fantastic track record," said Brian Sullivan, Celcuity's Chief Executive O

      11/29/21 5:00:00 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Dalvey David

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:49:35 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Director Buller Richard E was granted 1,029 shares, increasing direct ownership by 95% to 2,108 units (SEC Form 4)

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:48:37 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Nigon Richard

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:47:49 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Celcuity with a new price target

      Leerink Partners initiated coverage of Celcuity with a rating of Outperform and set a new price target of $29.00

      7/22/24 7:18:40 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Stifel initiated coverage on Celcuity with a new price target

      Stifel initiated coverage of Celcuity with a rating of Buy and set a new price target of $40.00

      2/22/24 6:21:40 AM ET
      $CELC
      Medical Specialities
      Health Care
    • H.C. Wainwright initiated coverage on Celcuity with a new price target

      H.C. Wainwright initiated coverage of Celcuity with a rating of Buy and set a new price target of $27.00

      12/8/23 7:38:12 AM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Financials

    Live finance-specific insights

    See more
    • Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancerApproximately $206 million in cash, cash e

      5/14/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

      MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information  To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this

      5/7/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025Presented encouraging preliminary overall survival data from the Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy at the 2024 SABCSApproximately $235.1 million in cash, cash equivalents and short-term investments at end of Q4 2024 expected to fund current clinical development program activities through 2026 Management to host webcast and conference call today, March 31, 2025, at 4:30 p.m. ET MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a c

      3/31/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care